Secura Bio

Corporate Profile

Secura Bio is a pharmaceutical company committed to giving patients access to innovative therapies.

Headquartered in Las Vegas, Nevada, Secura Bio has operations in the U.S. and offices in San Diego.

Leadership

Joseph M. Limber

President, CEO Secura Bio, Inc.

Mr. Limber brings to Secura Bio over 30 years of Executive level experience in both private and public companies. His career has included senior roles in major pharmaceutical companies such as Ciba-Geigy (now Novartis) and Syntex (now Roche), as well as more specialized life science companies including President/CEO roles at Sequus (now J&J), Praecis (now Glaxo), Aclara (now LabCorp), Prometheus (now Nestle Health Science) and Genoptix (now NeoGenomics). He has also been instrumental in leading commercialization efforts to launch/relaunch multiple therapeutics.

Mr. Limber has transacted over $2.8 billion through private and public financings and M&A for company and asset purchases, divestures, partnerships and IPO’s. Included in these are the >$217 million Aclara IPO, Prometheus sale to Nestle Health Science, and Genoptix sale to NeoGenomics.

Mark E. Spring

Chief Financial Officer

Mr. Spring has served as Secura’s Chief Financial Officer since it’s formation. He has 24 years of experience in the Life Sciences sector and has served as Chief Financial Officer for Genoptix, Sotera Wireless, Veracyte, Prometheus Laboratories and Hyperion Therapeutics. Mr. Spring also held senior level financial roles at MedImmune, Baxter Healthcare, Dade Behring, Caremark and Price Waterhouse.

Mr. Spring has a Bachelors degree in Business Administration from Monmouth College, post-graduate study at the University of Texas at Dallas and is a certified public accountant (active).

Brett K.E. Lund, J.D., M.B.A.

Chief Legal Officer

Brett K.E. Lund, J.D., M.B.A. is the Chief Legal Officer of Secura Bio. Prior to Secura, Mr. Lund was the Chief Legal Officer of Genoptix, Inc., an oncology diagnostics company, where he led the sale of Genoptix to NeoGenomics, Inc. (NASDAQ: NEO). Mr. Lund was previously the Chief Legal Officer of Gevo, Inc. (NSADAQ: GEVO), a biotechnology company, where he led their IPO and multiple rounds of venture financings. Mr. Lund was previously the Chief Executive Officer and board member of Agarigen, Inc. where he developed a biologic pharmaceutical manufacturing platform and led the sale of Agarigen to Intrexon, Inc. (NYSE: XON). Mr. Lund also served as the head of the legal, intellectual property and licensing group and biotechnology licensing manager for Syngenta Biotechnology’s (NYSE: SYT)) biopharma business. Mr. Lund also served as Associate General Counsel for Ford Motor Company, Inc.’s Wingcast subsidiary. Mr. Lund was previously a corporate attorney at the law firm of Cooley LLP.

Mr. Lund was named the “Best Corporate Counsel” by the Denver Business Journal. He was named “Forty Under 40” by the Denver Business Journal for being one of top forty business leaders under age 40 and named one of the “Most Influential Young Professionals” in Colorado by ColoradoBiz Magazine. Mr. Lund served on the Board of Directors of the Colorado BioScience Association (CBSA), the Board of Directors of the Colorado Cleantech Industry Association (CCIA) and on the Board of Directors of Gevo Development. Mr. Lund holds a J.D. from Duke Law School, an M.B.A. from Duke University’s Fuqua School of Business and a B.A. from the University of California, San Diego. He is a Certified Licensing Professional by the Licensing Executives Society and has been admitted to practice law in California and North Carolina.

William J. Davis

Senior Vice President, Commercial Operations

Mr. Davis has responsibility for Secura Bio Sales Operations worldwide. Bill brings more than 23 years of successful results in sales and marketing in the pharmaceutical/biotech industry. This includes deep experience in a broad array of commercial roles of increasing responsibility with therapeutics at Amgen, J&J and Pharmacia/Upjohn, including all aspects of marketing and sales development and execution on a global basis.

During his 12 years at Amgen, Bill’s responsibilities included: Director - U.S. & Global Marketing/Commercial Strategy Development Lead, Director - U.S. Commercial Lead Aranesp Oncology and Director, Global Leadership & Performance Decision Sciences, a CEO initiative to coordinate for efficiency of senior-level executives across GCO, R&D and Operations. At J&J and Pharmacia, Mr. Davis' responsibilities included sales leadership and brand launches in community, institution and government segments.

Mr. Davis has significant experience global oncology sales and marketing that includes LCM sales force deployment, managed care strategies and GPO partnerships.

Juan Estruch

Head of Corporate Development

Juan Estruch (Ph.D, MBA) has over 25 years of experience in the Life Science sector and has served in increasingly senior management roles initially in R&D and then in strategy and corporate development. He has served in senior positions or as head of corporate development for Ciba, Novartis, Diversa, Prometheus and most recently Genoptix. Dr. Estruch will serve as head of corporate development at Secura Bio. Dr. Estruch has a Ph.D. in Biochemistry and Molecular Biology from the University of Essen (Germany) and Valencia (Spain). He also obtained an MBA from the Fuqua School of Business, Duke University (USA).

Investor Contact

Mark Spring

Email: mark.spring@securabio.com
Phone: (858) 251-1414